Digiandomenico Anthony's Form 4 filing
ENDRA Life Sciences Inc. (NDRA) · filed May 3, 2023
- Accession no.
- 0001209191-23-026925
- Filed
- May 3, 2023, 4:07 PM ET
- Trade date
- May 2, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market purchases total $100.0K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Digiandomenico AnthonyCIK 0001083544 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 2, 2023 | Common Stock | PPurchaseAcquired | +83,333 | $1.20 | +$99,999.6 | 102,434 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 2, 2023 | Common Stock | PPurchaseAcquired | +41,667 | $0.01 | +$416.67 | 41,667 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.